Press releases

Press releases

31 August 2015  - Paris (France)

Ipsen announces publication in The Lancet Neurology of the results of the phase III randomized study (NCT01313299) showing efficacy and safety of Dysport® (abobotulinumtoxinA) in adult patients with upper limb spasticity (ULS)

03 August 2015  - Paris (France)

Ipsen’s partner, Lexicon Pharmaceuticals, announces positive results from TELESTAR phase 3 study showing that telotristat etiprate is effective in the treatment of carcinoid syndrome caused by neuroendocrine tumors not adequately controlled by somatostatin analogs

31 July 2015  - Paris (France)

Ipsen: 2015 half-year results

16 July 2015  - Paris (France)

Ipsen announces FDA approval of Dysport® (abobotulinumtoxinA) for injection in the treatment of upper limb spasticity in adults in the United States

02 July 2015  - Paris (France)

Ipsen provides an update on 2020 strategy and outlook at Investor Day

03 June 2015  - Paris (France)

Ipsen initiates a share buyback program Shares will be cancelled to compensate dilution resulting from its free share plans

02 June 2015  - Paris (France)

Ipsen confirms its eligibility for PEA-PME

29 May 2015  - Paris (France)

Combined Shareholders’ Meeting of IPSEN S.A. held on 27 May 2015

19 May 2015  - Paris (France)

Ipsen strengthens its presence in the oncology field with the acquisition of OctreoPharm Sciences, a company developing innovative radiopharmaceuticals for the diagnosis and treatment of neuroendocrine tumours

29 April 2015  - Paris (France)

Ipsen reports strong sales growth in Q1 2015 and raises guidance for the year

Updated on 31 July 2015